Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785928 · ClinicalTrials.gov registry record · Phase 2
A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT00785928 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 158 participants.
The verdict
NCT00785928, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks
Interventions
- DRUG Placebo
- BIOLOGICAL LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785928
The ClinicalTrials.gov registry entry for NCT00785928 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00785928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785928 about?
NCT00785928 is a clinical study titled "A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy". To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks
What is the current status of trial NCT00785928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2008-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00785928?
The interventions under investigation include: Placebo (DRUG), LY2127399 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00785928?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.